Skip to main content
1-featuredimage

Welcome to hubXchange's Antibody Therapeutics Xchange San Diego 2027.

This event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Lead Identification & Optimization, Formats & Scaffolds, Bi/Multispecifics, ADC Linker Design & Conjugation Technologies, and ADC Cytotoxic Payload.

Attendees can engage in roundtable discussions, pre-booked 1:1 meetings, presentations, and networking sessions with top industry experts, to foster collaboration and find innovative solutions to accelerate antibody therapeutics.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking.

San Diego | Tuesday 9th February 2027 | 08:00am - 05:40pm

VIEW AGENDA    REGISTER NOW    OUR PARTNERS    EVENT INFORMATION

Why choose hubXchange?


 

FULL AGENDA

Click the topic titles to find out more!

Loading
08:00
  1. Registration
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
08:30
  1. 30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Integral Molecular Logo
09:05
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Strategies for improving antibody affinity during lead optimization. How does antibody affinity influence internalization, efficacy, and pharmacokinetics? To what extent do CDX and PDX models reflect ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
    How can T-cell engagers effectively target antigens expressed at densities close to the limit of detection? How can peptide-centric specificity be achieved while minimising unwanted binding to the MHC ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    • How do you keep developability in check as molecular complexity increases? • How do you tune affinity, avidity, and valency to balance potency and safety? • What does it take to translate these mole ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    How is the ADC space continuing to grow, and why does it remain heavily focused on similar payload types? Which different payloads may have greater potential for patients who do not respond to establi ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    The current payload landscape – a TOPO1i world Development of novel single and dual payloads. What should we be looking for? Fit-for-purpose – identifying optimal payloads for specific tumor indicatio ...
10:10
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
10:40
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:10
  1. Morning Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:20
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Navigating vast sequence space: How can teams efficiently explore enormous antibody repertoires to pinpoint candidates with the right balance of affinity, specificity, and developability? Balancing po ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
     How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
     How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    Optimization of Drug Antibody Conjugates: Defining DAR, linker kinetics and stability, structural features and compositional stoichiometry, and analytical robustness Identification of limitations to d ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and safety of antibody-drug conjugates (ADCs)? What strategies can be employed to address and mitigate l ...
12:20
  1. Networking Lunch
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
13:20
  1. 30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Track antibody and ADC programs by leveraging CDD Vault’s chemically aware macromolecule capabilities. Heavy- and light- chain sequences can be registered and structurally annotated with  domains, hin ...
13:55
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
14:25
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
14:55
  1. Afternoon Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
15:05
  1. Lead Identification & Optimization
    30 mins
    • Lead Identification & Optimization
    The PioneerTM Antibody Discovery Platform is Bio-Rad’s biotherapeutic antibody generation service, centered around the Pioneer Antibody Library—one of the largest functional Fab libraries (225 billion ...
  2. Formats & Scaffolds
    30 mins
    • Formats & Scaffolds
    Antibody-based therapeutics generated with current technologies inherently exhibit product heterogeneity due to modifications occurring throughout production. Comprehensive characterization is therefo ...
    ProtaGene Logo No Background
  3. Bi/Multispecifics
    30 mins
    • Bi/Multispecifics
    Bispecific antibodies (BsAbs) offer transformative therapeutic potential, but their complex, non-native structure creates production challenges such as mispairing, low yield, and purification difficul ...
  4. ADC Linker Design & Conjugation Technologies
    30 mins
    • ADC Linker Design & Conjugation Technologies
    A central challenge in drug development is determining whether a therapeutic achieves appropriate tissue distribution and produces biologically meaningful effects. We present a drug-inclusive spatial ...
  5. ADC Cytotoxic Payload
    30 mins
    • ADC Cytotoxic Payload
15:40
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Where AI adds practical value in selecting antibody leads and prioritizing engineering changes. How to weigh conflicting predictions for affinity, specificity, immunogenicity, and developability along ...
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
    When does combining two mechanisms in a single molecule actually provide an advantage over a conventional antibody or combination therapy? What evidence do we need to see before deciding that a multis ...
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    Why potent T-cell activation often comes at the cost of increased cytokine release. Strategies to improve the therapeutic window while maintaining robust antitumor efficacy. Challenges in translating ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    How much of ADC linker selection is rational design versus platform default, and how rigorously are linker choices tested against alternatives? Are we over-indexing on linker chemistry rather than the ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    Are topoisomerase I inhibitor (TOP1i) payloads the default for solid tumor ADCs, or is the field over-converging on a single payload class with shared toxicity, resistance, and sequencing liabilities? ...
16:40
  1. Drinks-Canape Reception
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization

EVENT INFORMATION

3-featuredimage

DATES

San Diego
February 9, 2027

Tuesday 9th | 08:00am - 05:40pm

Marriott Del Mar

VENUE

Marriott Logo

11966 El Camino Real

San Diego

CA 92130

MAP

4-featuredimage

EVENT PARTNERS

OUR MEDIA PARTNERS

5-featuredimage

 REGISTRATION FORM - Register for free!

Complimentary Registration is only available for Senior Scientists & above, in Pharma & Bio Tech, with an active drug pipeline. For Service Providers, please click here.